The viral vectors & plasmid DNA market consists of sales of viral vectors & plasmid DNA and related services. The viral vectors & plasmid DNA are used for the delivery of cellular therapies, like gene therapy and immunotherapy, and also for treating some viral infections.
The global viral vectors & plasmid DNA market is expected to grow from $0.46 billion in 2019 to $0.60 billion in 2020 at a compound annual growth rate (CAGR) of 31.3%. The growth is mainly due to the outbreak of COVID 19 and requires targeted delivery of the drug to treat affected patients. The number of cases has been increasing resulting in a surge in demand for viral vectors & plasmid DNA. The market is expected to reach $1.05 billion in 2023 at a CAGR of 20.4%.